ArticlePharmacoEconomics - open2026

Cost-Effectiveness Analysis of Abrocitinib Compared with Dupilumab for Adolescents With Severe Atopic Dermatitis in Spain.

Rosa María Romero Jiménez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.